Effects of Atorvastatin on Atherosclerosis and Atherogenesis in Systemic Lupus Erythematosus: A Pilot Study
ISRN Immunology · 2014
DOI: 10.1155/2014/295239 ↗Abstract
Objective . The effect of statins on atherogenesis in systemic lupus erythematosus (SLE) is poorly known. To inform a wider trial we performed a pilot study evaluating the intima-media thickness of the common carotid artery (CIMT) and some oxidative [beta-2-glycoprotein-1 complexed with oxidised low density lipoprotein ( β 2 GPIoxLDL)], metabolic [paraoxonase (PON), nitrate ( NO 3 − ), nitrite ( NO 2 − ) and nitrotyrosine (NT)], inflammatory [C-reactive protein (CRP) and serum amyloid A (SAA)], and lipid markers before and after 1 year of treatment with 40 mg of oral atorvastatin (AT). Methods . Randomised, double blind, placebo controlled pilot study on consecutive SLE patients: 17 SLE patients were randomised into the AT arm and 20 into the placebo arm. CIMT was measured by high-resolution sonography, PONa by a spectrophotometric method, NO 3 − and NO 2 − by a colorimetric assay and oxLDL- β 2 GPI, NT, CRP, and SAA by Elisa. Results . After correction for age and disease duration oxLDL- β 2 GPI decreased by 27% ( P = 0.002 ) and PON/HDL ratio increased by 12% ( P = 0.01 ) but CIMT did not change. Conclusion . This pilot study revealed a decrease of oxLDL- β 2 GPI (oxidant marker) and an increase of PON/HDL ratio (antioxidant activity) after AT indicating a favourable effect of the drug on atherogenic pathways that should be explored on larger trials.
EUVIMED